Evidence map›Paper›PMID 34539818›Full record

ArticleTherapeutic advances in musculoskeletal disease2021

Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis.

Paul Studenic, Alessia Alunno, Daniela Sieghart, Holger Bang, Daniel Aletaha, Stephan Blüml, Helmuth Haslacher, Josef S Smolen, Roberto Gerli, Günter Steiner

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in musculoskeletal disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Paul StudenicDivision of Rheumatology, Department of Internal Medicine 3, Medical University of Vienna, Währinger Guertel 18-20, Vienna, 1090, Austria.ORCID https://orcid.org/0000-0002-8895-6941
Alessia AlunnoRheumatology Unit, Department of Medicine & Surgery, University of Perugia, Perugia, Italy.
Daniela SieghartDivision of Rheumatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria & Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria.
Holger BangOrgentec Diagnostika GmbH, Mainz, Germany.
Daniel AletahaDivision of Rheumatology, Department of Internal Medicine 3, Medical University Vienna, Vienna, Austria.
Stephan BlümlDivision of Rheumatology, Department of Internal Medicine 3, Medical University Vienna, Vienna, Austria.
Helmuth HaslacherDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Josef S SmolenDivision of Rheumatology, Department of Internal Medicine 3, Medical University Vienna, Vienna, Austria.
Roberto GerliRheumatology Unit, Department of Medicine & Surgery, University of Perugia, Perugia, Italy.
Günter SteinerDivision of Rheumatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria & Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria.
Medical University of Vienna · ATLudwig Boltzmann Institute for Digital Health and Prevention · ATUniversity of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo determine the diagnostic value of anti-acetylated peptide antibodies (AAPA) in patients with rheumatoid arthritis (RA).

methodsThree acetylated peptides (ac-lysine, ac-lysine.inv and ac-ornithine) derived from vimentin were employed to measure AAPA by enzyme-linked immunosorbent assay (ELISA) in sera of 120 patients with early RA (eRA), 195 patients with established RA (est RA), 99 healthy controls (HC), and 216 patients with other inflammatory rheumatic diseases. A carbamylated and a citrullinated version of the vimentin peptide were used additionally. Receiver operating characteristics and logistic regression analyses were used to assess the discriminative capacity of AAPA.

resultsAAPA were detected in 60% of eRA and 68.7% of estRA patients, 22.2% of HC, and 7.1- 30.6% of patients with other rheumatic diseases. Importantly, AAPA were also present in 40% of seronegative RA patients, while antibodies to the carbamylated peptide were detected less frequently. Diagnostic sensitivity of individual peptides for eRA was 28.3%, 35.8%, and 34% for ac-lysine, ac-ornithine, and ac-lysine.inv, respectively. Positive likelihood ratios (LR+) for eRA

conclusionAAPA are highly prevalent in early RA and occur also independently of RF and ACPA, thereby reducing the gap of seronegativity. Furthermore, multiple AAPA reactivity increased the specificity for RA, suggesting high diagnostic value of AAPA testing.

Indexed as

autoantibodiesdiagnostic testsinflammatory arthritisrheumatoid arthritisseronegative

Identifiers

PMID34539818
PMCPMC8445531
OpenAlexW3185160966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.